Form 4 for INBX Inhibrx Biosciences, Inc.
Accepted 2024-09-12 00:00:00 ET · period of report 2024-09-10 · accession 0002007919-24-000047 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-12 | 2024-09-10+ | INBX | Vuori Kristiina MD | Dir | P - Purchase | $15.07 | +6,636 | 13.8K | +93% | +$100.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-10 | P | A | 179 | $15.00 | 7,319 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-11 | P | A | 6,457 | $15.07 | 13,776 | D | — | — | (F1) The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |